Studies Open for recruitment at Johns Hopkins Singapore last updated: Jan-17 Liver Cancer

Main Criteria Study title Specification Principal Investigator Study information website SC, contact

Any HCC National Registry of Hepatocellular Carcinona Prof. Alex Chang Not applicable Xiaoying, 96446688

Protocol XL184-309: A Phase 3, Randomized, Double-blind, Controlled CHILD-PUGH A, after http://www.clinicaltrials.gov/ct2/show/NCT0190 Study of (XL184) vs Placebo in Subjects with Hepatocellular failed, has 2nd line Dr. Akhil Chopra 8426?term=Cabozantinib+%28XL184%29&rank= Ruth, 96421767 Carcinoma Who Have Received Prior Sorafenib. Open for recruitment, slots histological or cytological 7 remaining: 4 diagnosis of HCC https://clinicaltrials.gov/ct2/show/NCT02576509 ?term=A+Randomized%2C+Multi- A Randomized, Multi-center Phase III Study of versus Sorafenib CHILD-PUGH A, has center+Phase+III+Study+of+Nivolumab+versus+S 1st line as First-Line Treatment in Patients with Advanced Hepatocellular histological/cytological Dr. Akhil Chopra Xiaoying, 96446688 orafenib+as+First- Carcinoma diagnosis of HCC, ECOG 0-1 Line+Treatment+in+Patients+with+Advanced+He patocellular+Carcinoma&rank=1

https://clinicaltrials.gov/ct2/show/NCT02519348 A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and confirmed diagnosis of ?term=A+Study+of+Safety%2C+Tolerability%2C+ Tremelimumab Administered as Monotherapy and in Combination to unresectable HCC; must 2nd Line and above Dr. Akhil Chopra and+Clinical+Activity+of+MEDI4736+and+Tremel Elaine, 90887254 Subjects with Unresectable Hepatocellular Carcinoma. Part 2 pending to have progressed, refused or imumab+Administered+as+Monotherapy+and+i open early this year. intolerant to Sorafenib n+Combination+to+Subjects+with&rank=1

Breast Cancer Main Criteria Study title Specification SC, contact A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Her 2 negative, BRCA Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2- https://clinicaltrials.gov/ct2/show/NCT02163694 Up to 3rd line mutated, Failed Maximum 2 Dr. Chia Yee Hong Xiaoying, 96446688 Negative Metastatic or Locally Advanced Unresectable BRCA-Associated ?term=Veliparib&rank=20 lines of Breast Cancer

A Study of plus Capecitabine versus plus Capecitabine Her 2 positive. Must have http://www.clinicaltrials.gov/ct2/show/NCT0180 3rd line or more in patients with HER2+ metastatic breast cancer who have received two or failed 2 lines of HER 2 Dr. Lavina Bharwani Elaine, 90887254 8573?term=lapatinib+plus&rank=5 more prior HER2-directed regimens in the metastatic setting directed regimens.

Disease progression; A Randomized Open-Label Phase III Study of Single Agent previous tx with one or two https://clinicaltrials.gov/ct2/show/NCT02555657 2nd and 3rd line versus Treatment of Physician’s Choice Monotherapy for Metastatic Triple systemic treatment; biopsy Dr Lavina Bharwani ?term=pembrolizumab+physician%27s+choice&r Samantha, 83882481 Negative Breast Cancer (mTNBC) for PD-L1 positive status, ank=2 ECOG 0-1

Lung cancer A phase 1b open-label clinical trial of once daily oral treatment of afatinib plus weekly intraveneous infusion of BI 836845 in patients with EGFR Fail Afatinib, T790M https://clinicaltrials.gov/ct2/show/NCT02191891 2nd or 3rd line Dr Akhil Chopra Ruth, 96421767 mutant non-small cell with progression following prior EGFR negative. ?term=BI+836845+EGFR&rank=1 inhibitors. Study closing recruitment in Mar 2017 EGFR+, ECOG 0-2, Histologically confirmed Stage IIIB/IV https://clinicaltrials.gov/ct2/show/NCT02588261 An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs. adenocarcinoma NSCLC ?term=An+Open- 1st line or in First-line Treatment of Patients with Stage IIIB/IV Non-small Dr Alex Chung Belinda, 81025447 Subjects with mixed label%2C+Randomized+Phase+3+Efficacy+Study Cell Lung Cancer Tumors with EGFR Activating Mutations (SOLAR Study) histology are eligible if +of+ASP8273+vs.+Erlotinib+or+Gefitinib&rank=1 adenocarcinoma is the predominant histology Protocol: A Phase III, open-label, multicenter trial of EGFR and ALK (-), PD-L1 (MSB0010718C) versus platinum based doublet as a first line treatment of https://clinicaltrials.gov/ct2/show/NCT02576574 1st line positive, ECOG 0-1, Dr Akhil Chopra Siti Maryam, 96192498 recurrent or Stage IV PD L1+ non small cell lung cancer (Javelin). Current ?term=avelumab&rank=10 measurable lesion recruitment hold. Pls check with coordinator status.

must have concurrent Blood based detection of gene mutation in lung cancer patients with biopsy. 2 group: 1) Newly Blood Draw study Dr Akhil Chopra NA Yuana,96317249 known activating EGFR mutations who progress on first line TKI Dx NSCLC, or 2) progress on TKI

Gastric Cancer MEDI4736 in combination with tremelimumab, MEDI4736 monotherapy, Her 2 negative, Refractory and tremelimumab monotherapy will be safe and demonstrate clinical https://clinicaltrials.gov/ct2/show/NCT02340975 to platimnum or 2nd and 3rd line activity in subjects with metastatic or recurrent gastric or Dr. Alex Chang ?term=MEDI4736+monotherapy%2C+and+treme Belinda, 81025447 Fluoropyrimidine based gastroesophageal junction (GEJ) adenocarcinoma. Current status hold, for limumab&rank=1 chemotherapy interim analysis. Pls check status with coordinator. A Phase III Randomized Open-label Study of Single Agent Pembrolizumab fail 1st line, histo/cyto vs Physician's Choice of Single Agent Docetaxel, Paclitaxel or Irinotecan in confirmation of adeno or 2nd line Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell squamous CA of esophagus Dr Akhil Chopra https://clinicaltrials.gov/ct2/show/NCT02564263 Ruth, 96421767 Carcinoma of Esophagus that have progressed after First-Line Standard or Siewert Type I AdenoCA Therapy (KEYNOTE-181) of EGJ, ECOG 0-1 histologically or A Muticentre, Phase 1B/2 Study of Varlitinib in combination with cytologically confirmed 1st line Gemcitabine and Cisplatin for treatment Naïve advanced or metastatic advanced (unresectable) or Dr. Alex Chang https://clinicaltrials.gov/ct2/show/NCT02992340 Xiaoying, 96446688 biliary tract cancer. metastatic biliary tract cancer, ECOG 0-1 NPC Metastatic or locally A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of recurrent EBV positive, non- Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific 1st line NPC keratinizing and/or Dr. Akhil Chopra https://clinicaltrials.gov/show/NCT02578641 Xiaoying, 96446688 Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin undifferentiated NPC with As First Line Treatment For Advanced Nasopharyngeal Carcinoma Patients measurable disease Others

20mls of blood from NSCLC, Analytical validation of ClearCell FX for clinical application in personalized Blood Draw study liver and prostate - to Dr. Lavina Bharwani NA medicine isolate CTCs with the ClearCell FX platform. Siti Maryam, 96192498

Clinical applicability of RAS genotyping in circulating plasma DNA Blood Draw study Dr Jens Samol Xiaoying, 96446688 compared to tumor tissue from patients with metastatic colorectal cancer NA